Affect Therapeutics

Digital platform for addiction recovery support

New York City, New York, United States

About Affect Therapeutics

Affect Therapeutics provides a digital platform for addiction recovery, utilizing a science-based method known as contingency management. This approach combines financial incentives, therapy, and medication to encourage healthy behaviors and support individuals in overcoming their addictions. The service is fully digital, allowing clients to attend therapy sessions via secure video conference, which offers convenience and privacy compared to traditional rehab clinics. In addition to addiction treatment, Affect Therapeutics addresses other life challenges that can affect recovery, such as job searching and financial management, promoting a holistic view of recovery. The company likely operates on a subscription or fee-for-service model, ensuring that clients receive comprehensive support while the company funds its operations and growth. The goal of Affect Therapeutics is to help individuals not only achieve sobriety but also enhance their overall quality of life.

New York City, New YorkHeadquarters
2020Year Founded
$22.4MTotal Funding
SERIES_ACompany Stage
HealthcareIndustries
51-200Employees

Risks

Increased competition from similar digital health startups may dilute market share.
Rapid expansion plans could strain resources and affect service quality.
Potential data privacy concerns could lead to legal challenges.

Differentiation

Affect Therapeutics uses a unique contingency management approach for addiction treatment.
The company offers a fully digital, private, and accessible platform for recovery.
Affect Therapeutics provides holistic support, including job hunting and financial management assistance.

Upsides

Raised $16M in Series A funding for national and program expansion.
Holds outpatient treatment licenses in 20 states, aiming for majority U.S. coverage by 2023.
Growing telehealth adoption increases potential user base for Affect's digital platform.

Funding

Total raised$22.37 M
Latest valuation$80.00 M
StageSERIES_A